Valuation: Vivos Inc.

Market Cap 21.65M 19.32M 18.03M 16.38M 30.85M 2.09B 31.09M 216M 84.56M 1.06B 81.26M 79.5M 3.42B P/E 2024
-16.2x
P/E 2025 -10.2x
Enterprise Value 20.2M 18.04M 16.82M 15.29M 28.79M 1.95B 29.02M 202M 78.92M 994M 75.84M 74.2M 3.19B EV / Sales 2024
1,724x
EV / Sales 2025 438x
Free-Float
95.44%
Yield 2024 *
-
Yield 2025 -
1 day-3.75%
1 week+21.90%
Current month+18.00%
1 month+17.06%
3 months-31.24%
6 months-30.51%
Current year-14.37%
1 week 0.04
Extreme 0.0391
0.06
1 month 0.04
Extreme 0.0391
0.06
Current year 0.04
Extreme 0.0391
0.12
1 year 0.04
Extreme 0.0391
0.12
3 years 0.04
Extreme 0.0391
0.26
5 years 0.04
Extreme 0.0391
0.26
10 years 0.01
Extreme 0.0065
8
Manager TitleAgeSince
Chief Executive Officer 79 2016-12-13
President 44 2025-09-14
Director of Finance/CFO 59 2018-11-30
Director TitleAgeSince
Chairman 81 2016-12-13
Director/Board Member 79 2017-08-01
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 Buy

Chief Executive Officer

200,000 0.0405%
9/16/26 Buy

Chairperson

25,550 0.0052%
8/10/26 Buy

Chief Executive Officer

150,000 0.0304%
Change 5-day change 1-year change 3-year change Capi.($)
-3.75%+21.90%-33.63%-11.14% 22.37M
+0.83%-2.58%+21.71%+32.80% 243B
+1.34%-3.37%+3.20%+0.58% 152B
+2.41%+0.57%-7.82%+40.19% 143B
-1.45%-5.24%-57.00%-20.22% 61.14B
-0.81%-2.61%+12.04%+16.39% 49.85B
-0.14%-3.39%+19.41%+52.83% 47.74B
+1.29%-0.23%-20.20%-18.72% 47.74B
-0.35%+1.41%-5.76%+34.78% 45.9B
-2.11%-1.56%+165.06%+91.23% 41.3B
Average -0.21%-1.06%+9.70%+21.87% 83.1B
Weighted average by Cap. +0.17%-1.28%+9.95%+24.51%

Financials

2024 2025
Net sales 28K 24.99K 23.31K 21.18K 39.9K 2.71M 40.21K 280K 109K 1.38M 105K 103K 4.42M 68.38K 61.04K 56.94K 51.74K 97.46K 6.62M 98.22K 684K 267K 3.36M 257K 251K 10.8M
Net income -2.91M -2.6M -2.42M -2.2M -4.15M -282M -4.18M -29.09M -11.37M -143M -10.93M -10.69M -460M -3.07M -2.74M -2.55M -2.32M -4.37M -297M -4.4M -30.65M -11.98M -151M -11.51M -11.26M -484M
Net Debt -2.21M -1.98M -1.84M -1.67M -3.15M -214M -3.18M -22.12M -8.64M -109M -8.31M -8.13M -350M -1.44M -1.29M -1.2M -1.09M -2.06M -140M -2.07M -14.44M -5.64M -71.05M -5.42M -5.3M -228M
Projected Income Statement - Annual - Vivos Inc.
Logo Vivos Inc.
Vivos Inc. is a radiation oncology medical device company. The Company has developed an Yttrium-90-based injectable Precision Radionuclide Therapy medical device to treat tumors in animals (IsoPet) and humans (RadioGel). Using the Company’s proprietary hydrogel technology, PRnT uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers. University veterinary hospitals use the IsoPet Solutions division to demonstrate animal cancers’ safety and therapeutic effectiveness. RadioGel is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor.
Employees
1
Date Price Change Volume
26-10-07 US$0.0438 -3.23% 688,740
26-10-06 US$0.0453 +5.01% 1,488,686
26-10-05 US$0.0431 -5.90% 5,359,135
26-10-02 US$0.0458 -8.05% 663,531
26-10-01 US$0.0498 -0.38% 970,617
  1. Stock Market
  2. Stocks
  3. RDGL Stock